Higher incidence of delayed methotrexate clearance in pediatric acute lymphoblastic leukemia patients treated with imatinib

Background: Pediatric patients with Philadelphia chromosome positive (Ph+) or ABL-class fusion positive acute lymphoblastic leukemia (ALL) are currently treated with the tyrosine kinase inhibitor (TKI) imatinib added to a chemotherapy backbone that also contains several courses of high-dose methotre...

Full description

Bibliographic Details
Published in:EJC Paediatric Oncology
Main Authors: Inge M. van der Sluis, Nikita D. van Dijk, Leiah J. Brigitha, Freya M. Steinhauer, Rob Pieters
Format: Article
Language:English
Published: Elsevier 2023-12-01
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2772610X23001113